JP2025504017A5 - - Google Patents

Info

Publication number
JP2025504017A5
JP2025504017A5 JP2024544889A JP2024544889A JP2025504017A5 JP 2025504017 A5 JP2025504017 A5 JP 2025504017A5 JP 2024544889 A JP2024544889 A JP 2024544889A JP 2024544889 A JP2024544889 A JP 2024544889A JP 2025504017 A5 JP2025504017 A5 JP 2025504017A5
Authority
JP
Japan
Prior art keywords
wing segment
modified oligonucleotide
compound
combination according
linked nucleosides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024544889A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025504017A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2023/050687 external-priority patent/WO2023144750A1/en
Publication of JP2025504017A publication Critical patent/JP2025504017A/ja
Publication of JP2025504017A5 publication Critical patent/JP2025504017A5/ja
Pending legal-status Critical Current

Links

JP2024544889A 2022-01-28 2023-01-26 Ｂ型肝炎ウイルス感染症を処置するための組合せ療法 Pending JP2025504017A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263304091P 2022-01-28 2022-01-28
US63/304,091 2022-01-28
PCT/IB2023/050687 WO2023144750A1 (en) 2022-01-28 2023-01-26 Combination therapy for treating hepatitis b virus infections

Publications (2)

Publication Number Publication Date
JP2025504017A JP2025504017A (ja) 2025-02-06
JP2025504017A5 true JP2025504017A5 (https=) 2026-02-03

Family

ID=85172882

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024544889A Pending JP2025504017A (ja) 2022-01-28 2023-01-26 Ｂ型肝炎ウイルス感染症を処置するための組合せ療法

Country Status (8)

Country Link
US (1) US20250092401A1 (https=)
EP (1) EP4469161A1 (https=)
JP (1) JP2025504017A (https=)
KR (1) KR20240144245A (https=)
CN (1) CN118660704A (https=)
AU (1) AU2023213173B2 (https=)
CA (1) CA3243401A1 (https=)
WO (1) WO2023144750A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202340468A (zh) 2022-01-10 2023-10-16 中國大陸商杭州浩博醫藥有限公司 B型肝炎病毒(hbv)表現之調節
CN118667808B (zh) * 2023-08-22 2025-04-18 浙江柏拉阿图医药科技有限公司 双‐Gap修饰寡核苷酸及其在抗乙型肝炎和丁型肝炎病毒中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61447B1 (sr) 2011-04-21 2021-03-31 Glaxo Group Ltd Modulacija ekspresije virusa hepatitisa b (hbv)
EP4219767A1 (en) * 2016-06-17 2023-08-02 F. Hoffmann-La Roche AG Papd5 and papd7 inhibitors for treating a hepatitis b infection
KR20190057277A (ko) * 2016-06-24 2019-05-28 에모리 유니버시티 B형 간염 바이러스 치료용 포스포아미데이트
FI3692040T3 (fi) * 2017-10-05 2023-03-29 Glaxosmithkline Ip Dev Ltd Kemiallisia yhdisteitä

Similar Documents

Publication Publication Date Title
JP2022532211A5 (https=)
JP2688113B2 (ja) 多発性硬化症の治療のための置換アデニン誘導体を含む薬学的組成物
JP2025504017A5 (https=)
JP2008255121A (ja) 抗ｂ型肝炎ウイルス活性を有するヌクレオシド
JP2015528449A5 (https=)
US20210277403A1 (en) Methods and compositions for targeting pd-l1
JP2004525142A5 (https=)
JP2022515778A5 (https=)
JP2011079840A (ja) Ｂ型肝炎治療のための組合せ療法
JP2014144962A5 (https=)
TW202103698A (zh) 用於治療b型肝炎病毒感染之組合療法
JP2023543898A5 (https=)
CN114533739A (zh) 核苷类似物在制备预防或治疗胃肠道疾病药物中的应用
TW202140789A (zh) 靶向ｐｄ—ｌ１之方法及組合物
JP2024544532A5 (https=)
CN112121044B (zh) 氨来占诺用于制备抗肝炎病毒药物的用途
JP2023520405A5 (https=)
JP2002515892A (ja) サイトカインが関係する疾患治療法
TW200306185A (en) Combinations comprising EPOTHILONES and anti-metabolites
CN111971049A (zh) 促进免疫应答
JP2002538171A (ja) 抗ウイルス剤の医薬的組合せ
CN1447692A (zh) 药物释放至肝细胞和治疗黄病毒感染的方法
CN114057816B (zh) 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用
JP2024528659A5 (https=)
CN101031308A (zh) 由rna依赖性dna聚合酶活化的药物前体